Article Sidebar

pdf
Date Published: 31/12/2025
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v557i2.16706
Issue
Vol. 557 No. 2 (2025)
Section
Các bài báo
How to Cite
Nguyễn, T. Đức, & Lê, Q. T. (2025). ASSOCIATION BETWEEN CREATININE/CYSTATIN C RATIO AND CLINICAL CHARACTERISTICS IN PATIENTS WITH DIABETES MELLITUS. Vietnam Medical Journal, 557(2). https://doi.org/10.51298/vmj.v557i2.16706

ASSOCIATION BETWEEN CREATININE/CYSTATIN C RATIO AND CLINICAL CHARACTERISTICS IN PATIENTS WITH DIABETES MELLITUS

Tấn Đức Nguyễn, Quốc Tuấn Lê

Main Article Content

Abstract

Background: The serum creatinine-to–cystatin C ratio (Cre/CysC) has been proposed as a proxy for low muscle mass and adverse outcomes. Evidence in patients with type 2 diabetes (T2D) remains limited. Objective: To examine the association between serum Cre/CysC and clinical as well as biochemical characteristics in T2D. Methods: We conducted a cross-sectional analytical study of 124 adults with T2D attending the outpatient clinic of 175 Military Hospital (January–May 2025). Data included age, sex, diabetes duration, BMI, fasting plasma glucose, HbA1c, creatinine, and cystatin C. Cre/CysC was calculated as creatinine (mg/dL) divided by cystatin C (mg/L) [×100 if applicable]. Correlations and linear regression of Cre/CysC with age, BMI, diabetes duration, glucose and HbA1c were performed. Results: The median age was 51 years; diabetes duration 5 years, BMI 21.72 kg/m2. The median Cre/CysC was 11.79; it correlated inversely with BMI, fasting glucose, HbA1c (all p<0.05). Associations remained significant after multivariable adjustment. Conclusion: Lower Cre/ CysC is associated with adverse metabolic profile and longer diabetes duration in T2D. Cre/CysC may serve as a supportive indicator of low muscle mass and metabolic dysregulation, warranting studies with direct muscle measurements and outcome validation

Article Details

Keywords

creatinine/cystatin C ratio; type 2 diabetes; sarcopenia; eGFR; BMI.

References

Tabara, Y., et al., Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass in older adults: J-SHIPP study. Clin Nutr, 2020. 39(6): p. 1857-1862.
2. Lee, H.S., et al., Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. J Clin Med, 2020. 9(10).
3. Sun, H., et al., IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022. 183: p. 109119.
4. Wang, D., et al., Imaging of Sarcopenia in Type 2 Diabetes Mellitus. Clin Interv Aging, 2024. 19: p. 141-151.
5. Yang, Q., et al., Cre/CysC ratio may predict muscle composition and is associated with glucose disposal ability and macrovascular disease in patients with type 2 diabetes. BMJ Open Diabetes Res Care, 2021. 9(2).
6. Shin, J.Y., Low serum creatinine to cystatin C ratio is independently associated with sarcopenia and high carotid plaque score in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis, 2022. 32(6): p. 1454-1462.
7. Qiu, S., et al., Changes in creatinine-to-cystatin C ratio over 4 years, risk of diabetes, and cardiometabolic control: The China Health and Retirement Longitudinal Study. J Diabetes, 2021. 13(12): p. 1025-1033.
8. Nishimura, A., et al., Sex-related differences in frailty factors in older persons with type 2 diabetes: a cross-sectional study. Ther Adv Endocrinol Metab, 2019. 10: p. 2042018819833304.
9. Zhang, L., et al., Serum creatinine/cystatin C ratio is a predictor of all-cause mortality for older adults over 80 years. Heliyon, 2023. 9(3): p. e14214.